Literature DB >> 12581276

The local lymph node assay: past, present and future.

Ian Kimber1, R J Dearman, D A Basketter, C A Ryan, G F Gerberick.   

Abstract

The local lymph node assay (LLNA) was developed originally as a method for the identification of chemicals that have the potential to cause skin sensitization and allergic contact dermatitis. The assay is based on an understanding that the acquisition of contact sensitization is associated with, and dependent upon, the stimulation by chemical allergens of lymphocyte proliferative responses in skin-draining lymph nodes. Those chemicals that provoke a defined level of lymph node cell (LNC) proliferation (a 3-fold or greater increase compared with concurrent vehicle controls) are classified as skin sensitizers. Following its original inception and development, the LLNA was the subject of both national and international interlaboratory collaborative trials, and of very detailed comparisons with other test methods and with human skin sensitization data. The assay has now been validated fully as a stand-alone test for the purposes of hazard identification. In recent years, there has been a growing interest also in the use of the LLNA to assess the potency of contact allergens and in risk assessment. There is reason to believe that the extent of skin sensitization achieved is associated with the vigour of LNC proliferation induced in draining nodes. Given this relationship, the relative potency of skin sensitizing chemicals is measured in the LLNA by derivation of an EC3 value, this being the concentration of chemical required to provoke a 3-fold increase in the proliferation of LNC compared with controls. Experience to date indicates that relative potency as determined using this approach correlates closely with what is known of the activity of skin sensitizing chemicals in humans. In this article, we review the development, evaluation and validation of the LLNA for the purposes of hazard identification, and the more recent application of the method for evaluation of potency in the context of risk assessment. In addition, we consider what new applications and modifications are currently being investigated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12581276     DOI: 10.1034/j.1600-0536.2002.470601.x

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  7 in total

Review 1.  Skin and respiratory chemical allergy: confluence and divergence in a hybrid adverse outcome pathway.

Authors:  Ian Kimber; Alan Poole; David A Basketter
Journal:  Toxicol Res (Camb)       Date:  2018-01-26       Impact factor: 3.524

Review 2.  Immunotoxicology: role in the safety assessment of drugs.

Authors:  Jacques Descotes
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  The LLNA: A Brief Review of Recent Advances and Limitations.

Authors:  Stacey E Anderson; Paul D Siegel; B J Meade
Journal:  J Allergy (Cairo)       Date:  2011-06-16

Review 4.  In vitro methods for hazard assessment of industrial chemicals - opportunities and challenges.

Authors:  Chin Lin Wong; Sussan Ghassabian; Maree T Smith; Ai-Leen Lam
Journal:  Front Pharmacol       Date:  2015-05-05       Impact factor: 5.810

5.  Prediction of Chemical Respiratory and Contact Sensitizers by OX40L Expression in Dendritic Cells Using a Novel 3D Coculture System.

Authors:  Izuru Mizoguchi; Mio Ohashi; Yukino Chiba; Hideaki Hasegawa; Mingli Xu; Toshiyuki Owaki; Takayuki Yoshimoto
Journal:  Front Immunol       Date:  2017-08-04       Impact factor: 7.561

6.  Skin sensitization: Uncertainties, challenges, and opportunities for improved risk assessment.

Authors:  Nicola Gilmour; Ian Kimber; Jason Williams; Gavin Maxwell
Journal:  Contact Dermatitis       Date:  2018-12-07       Impact factor: 6.600

Review 7.  Contact dermatitis.

Authors:  Pamela L Scheinman; Marc Vocanson; Jacob P Thyssen; Jeanne Duus Johansen; Rosemary L Nixon; Kate Dear; Nina C Botto; Johanna Morot; Ari M Goldminz
Journal:  Nat Rev Dis Primers       Date:  2021-05-27       Impact factor: 52.329

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.